HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

490.383

-13.015-2.59%

Number of Gainers:6

Number of Losers:23

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:82.72M

Turnover:2.69B

Market Cap:313.43B

Float Cap:277.25B

Loading ...

AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer

HK Stock Market Flash: PEIJIA-B (09996) Climbs Over 5% Again, Lifts Full-Year TAVR Volume Guidance After Strong Interim Results

HK Biotech Shares Surge as CansinoBio Jumps Over 18%

Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial

MT Newswires Live

Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint

Finally Tasting the Gains in the Healthcare Sector Today!

HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off

Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy

Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%

MT Newswires Live

AKESO's Novel Dual Antibody Achieves Positive Phase III Results in Biliary Tract Cancer, Marking First Solid Tumor Expansion Beyond Lung Cancer

Akeso - Ivonescimab Plus Chemo Meets Primary Endpoint with Significant Os Benefit in 1L BTC

THOMSON REUTERS

Akeso - Harmoni-Gi1 First Phase Iii Study to Show Significant Os Benefit Versus Global Standard in Biliary Tract Cancer

THOMSON REUTERS

Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: Harmoni-Gi1 Meets Primary Endpoint

THOMSON REUTERS

Akeso - Study Meets Key Secondary Endpoints of Progression-Free Survival and Objective Response Rate

THOMSON REUTERS

Electromed's Q4 Revenue Slightly Beats Estimates on Homecare Strength

Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?

Simply Wall St.

China's Weigao H1 Profit Falls 23% as Price Drops, Competition Hit Margins

C-Mer Eye Care's H1 Revenue Rises, Net Profit Flat

China's Neptunus Interlong H1 Revenue Falls

Sweden's SyntheticMR Q2 Sales Rise, Loss Narrows on cNeuro Strength, India Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":490.383,"timestamp":1788250091886,"preClose":503.39795,"halted":0,"volume":82724645,"delay":0,"changeRate":-0.025854,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-13.014954,"latestTime":"09-01 16:00:00","open":503.51608,"high":505.9005,"low":489.5706,"amount":2688849767,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.003099,"increases":6,"decrements":23,"flats":3,"marketCap":313429262448,"floatMarketCap":277247178824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":490.383,"volume":82724645,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.003099,"peRate":127.340212,"marketCap":313429262448,"floatMarketCap":277247178824,"timestamp":1788250091886,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":23,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1147226125","title":"AKESO Surges Over 9% in Session as Evonex Achieves Positive Phase III Results in Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1147226125","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147226125?lang=en_us&edition=fundamental","pubTime":"2026-08-26 10:31","pubTimestamp":1787711462,"startTime":"0","endTime":"0","summary":"Shares of AKESO (09926) surged more than 9% during intraday trading before paring gains to trade 6.81% higher at HK$94.85, with turnover reaching HK$814 million. The sharp move followed the company's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","BK4134","LU0417516571.SGD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1961090484.USD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","III","LU1794554557.SGD","LU1720050803.USD","09926","LU0348767384.USD","LU0348735423.USD","LU0634319403.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","KURE","BK1574","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160004309","title":"HK Stock Market Flash: PEIJIA-B (09996) Climbs Over 5% Again, Lifts Full-Year TAVR Volume Guidance After Strong Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1160004309","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160004309?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:54","pubTimestamp":1787709256,"startTime":"0","endTime":"0","summary":"Shares of PEIJIA-B (09996) extended their rally, climbing more than 5% during Monday's trading session. At the time of writing, the stock was up 3.14% at HK$5.58, with turnover reaching HK$1.25...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","VXUS","159891","BK4585","BK1100","KCAI","BK1583","BK4588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176024527","title":"HK Biotech Shares Surge as CansinoBio Jumps Over 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176024527","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176024527?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:50","pubTimestamp":1787709027,"startTime":"0","endTime":"0","summary":"Shares of Hong Kong-listed biopharmaceutical companies continued their recent rally on Tuesday, with CANSINOBIO surging 18%, 信达生物 climbing over 11% following its earnings release, 云顶新耀 rising more...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","06185","KCAI","161726","BK1574","BK4588","BK1515","BK1191","BK4585","VXUS","BK1161","399441","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766269","title":"Akeso's Ivonescimab Meets Primary Endpoint in Phase 3 Biliary Tract Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766269","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766269?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:41","pubTimestamp":1787708502,"startTime":"0","endTime":"0","summary":"Akeso  said its PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy met the primary endpoint in a Phase 3 trial for first-line treatment of advanced biliary tract cancer.The trial met its primary endpoint of overall survival, with key secondary endpoints of progression-free survival and objective response rate also met, according to a Wednesday filing with the Hong Kong bourse.The HARMONi-GI1 study enrolled 682 patients, marking ivonescimab's first positive Phase 3 result in gastrointestinal tumors, Akeso said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0561508036.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","BK1161","LU0348784397.USD","LU0348783233.USD","LU0417516902.SGD","09926","LU0348735423.USD","LU2476274720.SGD","LU2778985437.USD","KURE","LU1961090484.USD","LU2476274308.USD","LU0348766576.USD","IE00B543WZ88.USD","LU1720050803.USD","LU0348825331.USD","LU2488822045.USD","LU0417516738.SGD","LU0417516571.SGD","LU0540923850.HKD","BK1574","LU2399975544.HKD","LU0348827113.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766696","title":"Akeso Says Ivonescimab Plus Chemo Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766696","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662766696?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:29","pubTimestamp":1787707747,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says Ivonescimab Plus Chemo Meets Primary EndpointAug 26 (Reuters)-Akeso Inc9926.HK:IVONESCIMAB PLUS CHEMO MEETS PRIMARY ENDPOINT WITH SIGNIFICANT OS BENEFIT IN 1L BTCFurther company coverage:9926.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44M0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","LU2778985437.USD","LU2488822045.USD","BK1161","LU0348783233.USD","IE00BPRC5H50.USD","BK1574","LU0540923850.HKD","LU1794554557.SGD","LU0348784397.USD","09926","LU0348766576.USD","LU0417516571.SGD","LU2399975544.HKD","KURE","IE00B543WZ88.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","LU2476274308.USD","LU1961090484.USD","LU0417516738.SGD","LU0348735423.USD","LU0417516902.SGD","LU0348827113.USD","LU0348825331.USD","LU0561508036.HKD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192662003","title":"Finally Tasting the Gains in the Healthcare Sector Today!","url":"https://stock-news.laohu8.com/highlight/detail?id=1192662003","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192662003?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:21","pubTimestamp":1787707280,"startTime":"0","endTime":"0","summary":"After Bessent detailed the \"economic war\" tactics against Iran, oil prices took a sharp dive. This isn't because the conflict has reached its conclusion; rather, the US Treasury is expanding the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115078027","title":"HK Stock Market Highlights: Haizhi Tech's H1 FY2026 Revenue Jumps 70.4% as Agent Business Takes Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1115078027","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115078027?lang=en_us&edition=fundamental","pubTime":"2026-08-26 09:17","pubTimestamp":1787707028,"startTime":"0","endTime":"0","summary":"Key corporate developments this week: GenFleet Therapeutics-B (02595) has initiated a Phase II study evaluating GFH375, an oral KRAS G12D inhibitor, as a first-line treatment for non-small cell lung...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","00660","BK4585","BK1589","LU1961090484.USD","LU0417516902.SGD","BK1586","LU2488822045.USD","LU0348827113.USD","KCAI","BK4588","BK1574","00354","IE00B543WZ88.USD","VXUS","BK1526","LU0417516571.SGD","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348825331.USD","LU2476274308.USD","LU0417516738.SGD","BK1518","LU1794554557.SGD","BK1161","BK1237","LU1720050803.USD","02595","LU0348783233.USD","LU2399975544.HKD","LU0634319403.HKD","LU2476274720.SGD","LU0348766576.USD","LU0348735423.USD","LU0540923850.HKD","09926","LU0348784397.USD","BK1155","KURE","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129968594","title":"Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1129968594","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129968594?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:50","pubTimestamp":1787705420,"startTime":"0","endTime":"0","summary":"On August 25, Novartis AG (NVS.US) announced that its radiopharmaceutical lutetium [177Lu] vipivotide tetraxetan (Chinese brand name: Paiweitou) received a new indication approval in China. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS","IE00BJT1NW94.SGD","LU0070302665.USD","BK4532","BK1574","IE00B4R5TH58.HKD","01477","IE0002141913.USD","IE00B2B36J28.USD","LU0211331839.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE00BJJMRZ35.SGD","MEDX","BK4578","IE0009355771.USD","LU0208291251.USD","BK1191","BK4588","PPH","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662639247","title":"Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639247","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662639247?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:23","pubTimestamp":1787703832,"startTime":"0","endTime":"0","summary":"Zai Lab  incurred $101.8 million in net loss in the first half of the year, wider by 14% from $89.2 million a year earlier, according to a Wednesday filing to the Hong Kong stock exchange.Loss per share came in at $0.09 compared with $0.08 a year earlier, the biopharmaceutical company said.Net product revenue during the period fell 6% to $201.3 million from $214.7 million a year prior.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1588","BK1574","LU2488822045.USD","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197055899","title":"AKESO's Novel Dual Antibody Achieves Positive Phase III Results in Biliary Tract Cancer, Marking First Solid Tumor Expansion Beyond Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1197055899","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197055899?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:42","pubTimestamp":1787701336,"startTime":"0","endTime":"0","summary":"AKESO (09926) has announced that its independently developed, first-in-class bispecific antibody, 依达方® (ivonescimab, PD-1/VEGF), combined with chemotherapy, demonstrated a statistically significant...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0348766576.USD","KURE","LU1961090484.USD","BK4134","BK1574","LU0561508036.HKD","LU2399975544.HKD","09926","LU1720050803.USD","LU2476274720.SGD","LU0540923850.HKD","LU2476274308.USD","LU2488822045.USD","BK1161","III","LU0348783233.USD","LU0348767384.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516738.SGD","LU0634319403.HKD","LU0348735423.USD","LU2778985437.USD","LU0348784397.USD","LU0417516571.SGD","LU0348827113.USD","LU1794554557.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662685897","title":"Akeso - Ivonescimab Plus Chemo Meets Primary Endpoint with Significant Os Benefit in 1L BTC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662685897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662685897?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:01","pubTimestamp":1787698884,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nFWN44M0TW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KURE","BK1574","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD","LU2476274308.USD","LU0348766576.USD","BK1161","IE00B5MMRT66.SGD","LU0348825331.USD","LU2399975544.HKD","LU1720050803.USD","LU0348783233.USD","LU0561508036.HKD","LU1794554557.SGD","LU0417516571.SGD","LU2778985437.USD","LU0417516738.SGD","LU0417516902.SGD","LU2476274720.SGD","LU0348827113.USD","09926","LU2488822045.USD","LU0348735423.USD","LU0348767384.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752407","title":"Akeso - Harmoni-Gi1 First Phase Iii Study to Show Significant Os Benefit Versus Global Standard in Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752407?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:00","pubTimestamp":1787691600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA5XV27P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1794554557.SGD","LU1720050803.USD","LU0348783233.USD","LU1961090484.USD","KURE","LU0348766576.USD","LU0348784397.USD","LU0348825331.USD","LU0417516738.SGD","BK1161","LU2476274308.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0540923850.HKD","LU2778985437.USD","09926","LU0348827113.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0417516571.SGD","BK1574","LU2488822045.USD","LU0561508036.HKD","LU2399975544.HKD","LU0348735423.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662524007","title":"Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: Harmoni-Gi1 Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662524007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662524007?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:00","pubTimestamp":1787691600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA5XV27P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B5MMRT66.SGD","LU0634319403.HKD","LU2476274720.SGD","LU0348825331.USD","LU0561508036.HKD","LU0348766576.USD","LU0348784397.USD","LU0348783233.USD","LU0348827113.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU2476274308.USD","LU0417516902.SGD","LU1961090484.USD","09926","IE00BPRC5H50.USD","LU1720050803.USD","LU2399975544.HKD","LU0417516571.SGD","LU2488822045.USD","BK1161","LU0540923850.HKD","LU2778985437.USD","KURE","LU1794554557.SGD","BK1574","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662401752","title":"Akeso - Study Meets Key Secondary Endpoints of Progression-Free Survival and Objective Response Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2662401752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662401752?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:00","pubTimestamp":1787691600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA5XV27P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0540923850.HKD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","KURE","BK1161","LU0634319403.HKD","LU0417516738.SGD","LU1794554557.SGD","LU0348767384.USD","09926","LU0348825331.USD","LU0348783233.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU2476274308.USD","LU0561508036.HKD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662278754","title":"Electromed's Q4 Revenue Slightly Beats Estimates on Homecare Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2662278754","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662278754?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:15","pubTimestamp":1787688928,"startTime":"0","endTime":"0","summary":"Electromed's Q4 revenue slightly beats estimates on homecare strengthOverviewUS airway clearance device maker's fiscal Q4 revenue rose, slightly beating analyst expectationsFiscal Q4 net income rose 5","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELMD","BK1100","BK4082","BK1574","BK1583","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662349759","title":"Is HBM Holdings (SEHK:2142) Fully Valued After Its HBM7004 IND Approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662349759","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662349759?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:18","pubTimestamp":1787674691,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors.\nSee our latest analysis for HBM Holdings.\nThe HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-hbm7004-ind","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-hbm7004-ind","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HBMX","BK4168","HBM","BK4588","DRAM","DRMY","MULL","RAMZ","MUYY","DRMP","02142","DISK","MUG","MUD","RAM","COPP","DRAL","MUZ","MUU","MIC","BK1574","DCF","BK1583","BK1161","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771732","title":"China's Weigao H1 Profit Falls 23% as Price Drops, Competition Hit Margins","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:55","pubTimestamp":1787662510,"startTime":"0","endTime":"0","summary":"China's Weigao H1 profit falls 23% as price drops, competition hit marginsOverviewChina medical device maker's H1 revenue rose 3.1% yr/yr, net profit fell 23.2%Gross margin dropped 3.4 percentage poin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1574","LU0173614495.USD","BK1583","BK1100","LU0287142896.SGD","01066","BK1222","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662873220","title":"C-Mer Eye Care's H1 Revenue Rises, Net Profit Flat","url":"https://stock-news.laohu8.com/highlight/detail?id=2662873220","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662873220?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:52","pubTimestamp":1787662323,"startTime":"0","endTime":"0","summary":"C-Mer Eye Care's H1 revenue rises, net profit flatOverviewEye care provider's revenue rose 8.5% yr/yr for six months ended JuneNet profit attributable to equity holders increased 0.2% yr/yrAdjusted pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1516","BK1574","03309","BK1209","BK1100","BK1219","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662644732","title":"China's Neptunus Interlong H1 Revenue Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2662644732","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662644732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:41","pubTimestamp":1787661677,"startTime":"0","endTime":"0","summary":"China's Neptunus Interlong H1 revenue fallsOverviewChina pharma and medical device firm's H1 revenue fell year-over-yearNet income attributable to owners declined for the half-year periodNo interim di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09996","BK0239","BK1161","688428","01167","BK1583","BK1100","08329","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662399732","title":"Sweden's SyntheticMR Q2 Sales Rise, Loss Narrows on cNeuro Strength, India Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662399732","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662399732?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:36","pubTimestamp":1787661380,"startTime":"0","endTime":"0","summary":"Sweden's SyntheticMR Q2 sales rise, loss narrows on cNeuro strength, India growthOverviewSweden medical imaging firm's Q2 sales rose 13% yr/yrOperating loss for Q2 narrowed to -6.5 mln SEK from -8.6 m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09996","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":9,"totalSize":383,"code":"91000000","status":"200"}]}}